Conditions: Psychiatric Illness Healthy
Keywords: healthy individuals schizophrenia schizoaffective disorder learning memory cognitive enhancement fMRI
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 44
Healthy volunteers: yes

Brief summary:
The present study proposes to evaluate the potential cognitive enhancing effects of GLYX-13, an NMDAR partial agonist, among a group of healthy adults and those with psychiatric illness on a series of functional magnetic resonance imaging (fMRI) learning and memory tasks.

Detailed description:
In a single blind randomized parallel group design, we will evaluate the whether a single dose of GLYX-13 vs. placebo increases cognitive performance on tasks of learning, declarative memory, and working memory, and associated task-related increases in blood oxygen level-dependent (BOLD) activation in hippocampus and dorsolateral prefrontal cortex, respectively. Positive findings will provide biomarker evidence for GLYX-13 effects on neural systems underlying these cognitive processes.

Arms:
arm 1: Single IV infusion of GLYX-13, 5mg/kg, arm 2: Single IV administration of placebo

Interventions: intervention 1: GLYX-13 intervention 2: Placebo
Intervention descriptions: intervention 1: Single injection (5 mg/kg) of GLYX-13, an NMDAR partial agonist intervention 2: Single injection of placebo (saline)

Protocol document: